Amneal Pharmaceuticals, Cash Over Time

AMRX Stock  USD 8.32  0.09  1.07%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Amneal Pharmaceuticals, Performance and Amneal Pharmaceuticals, Correlation.
  
At this time, Amneal Pharmaceuticals,'s Price To Free Cash Flows Ratio is fairly stable compared to the past year. Cash Conversion Cycle is likely to rise to 268.72 in 2024, whereas Begin Period Cash Flow is likely to drop slightly above 33.5 M in 2024.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amneal Pharmaceuticals,. If investors know Amneal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amneal Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.75)
Earnings Share
(0.86)
Revenue Per Share
9.16
Quarterly Revenue Growth
0.133
Return On Assets
0.0594
The market value of Amneal Pharmaceuticals, is measured differently than its book value, which is the value of Amneal that is recorded on the company's balance sheet. Investors also form their own opinion of Amneal Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Amneal Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amneal Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Amneal Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amneal Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Amneal Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amneal Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Cash Analysis

Compare Amneal Pharmaceuticals, and related stocks such as Alkermes Plc, Neurocrine Biosciences, and Intracellular Th Cash Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
ALKS3.1 M83.6 M97 M167.6 M224.1 M181.1 M186.4 M191.3 M266.8 M203.8 M273 M337.5 M292.5 M457.5 M480.3 M
NBIX11.3 M50.1 M63.8 M44.8 M31 M74.2 M83.3 M254.7 M141.7 M112.3 M801 M340.8 M262.9 M251.1 M131.9 M
ITCI13.7 M13.7 M19.1 M35.2 M61.3 M47.2 M48.6 M37.8 M54.9 M107.6 M60 M92.4 M148.6 M147.8 M74 M
DVAX4.3 M31.9 M7.6 M23.1 M49.5 M44.8 M24.3 M26.6 M49.3 M39.9 M32.1 M436.2 M202 M150.3 M157.8 M
AMPH50.2 M50.2 M50.2 M53.6 M67.8 M66.1 M72.4 M65.6 M86.3 M73.7 M92.6 M126.4 M156.1 M144.3 M96.7 M
COLL7.6 M7.6 M7.6 M7.6 M1.6 M95.7 M153.2 M118.7 M146.6 M170 M174.1 M186.4 M173.7 M238.9 M146.7 M
IRWD62.4 M87.3 M136.7 M75.5 M74.3 M261.3 M54 M125.7 M173.2 M177 M362.6 M620.1 M656.2 M92.2 M87.5 M
ANIP2.8 M57.2 M34.8 M11.1 M169 M154.7 M27.4 M31.1 M43 M62.3 M7.9 M100.3 M48.2 M221.1 M232.2 M
PAHC2.4 M53.9 M27.4 M11.8 M29.2 M33.6 M56.1 M29.2 M57.6 M36.3 M50.2 M74.2 M41.3 M70.6 M74.1 M
PROCMMMMMMMMMM4.2 M72.1 M43 M49.5 M33.4 M
EOLSMMMMMM187 K0.093.2 M109.9 M102.6 M146.3 M53.9 M62.8 M70 M
ASRT4.1 M24 M77.9 M276 M566.4 M209.8 M177.4 M128.1 M110.9 M42.1 M20.8 M36.8 M64.9 M73.4 M80.2 M
LFCR14.2 M22.2 M13.7 M14.2 M14.1 M9.9 M5.4 M2.9 M1.1 M360 K1.3 M1.6 M1.6 M8.5 M10.6 M

Amneal Pharmaceuticals, and related stocks such as Alkermes Plc, Neurocrine Biosciences, and Intracellular Th Cash description

Cash refers to the most liquid asset of Amneal Pharmaceuticals,, which is listed under current asset account on Amneal Pharmaceuticals, Class balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Amneal Pharmaceuticals, customers. The amounts must be unrestricted with restricted cash listed in a different Amneal Pharmaceuticals, account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

My Equities

My Current Equities and Potential Positions

Amneal Pharmaceuticals, Class
AMRX
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Business Address400 Crossing Boulevard,
ExchangeNew York Stock Exchange
USD 8.32

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.